DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

DBV Technologies, a clinical-stage biopharmaceutical company based in Châtillon, France, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 9, 2025. Daniel Tassé, the company’s Chief Executive Officer, will engage in a fireside chat at 11:30 AM ET, providing a platform for discussing DBV’s advancements and strategic vision. Investors can access a live webcast of the discussion, which will later be archived for 90 days on the company’s website.

DBV Technologies specializes in developing innovative treatment solutions for food allergies and other immunologic conditions marked by significant unmet medical needs. At the forefront of its efforts is the proprietary VIASKIN® patch technology, designed to deliver microgram doses of biologically active compounds to the immune system through the skin. This method, known as epicutaneous immunotherapy (EPIT), is non-invasive and aims to re-educate the immune system to foster desensitization to allergens by utilizing the skin’s inherent immune tolerizing properties.

The company is particularly focused on food allergies, which affect millions, including vulnerable groups such as toddlers and young children. DBV is conducting clinical trials for its VIASKIN Peanut product, targeting peanut allergies in toddlers aged 1 to 3 years and children aged 4 to 7 years.

DBV Technologies is listed on Euronext Paris (Ticker: DBV) and the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309), with North American operations located in Warren, NJ. For more information, stakeholders are encouraged to visit DBV's website and follow their updates on social media platforms.

DBV Technologies is poised to capture attention at the H.C. Wainwright 27th Annual Global Investment Conference, slated for September 9, 2025. As a clinical-stage biopharmaceutical company specializing in food allergies and immunologic conditions, DBV’s proprietary VIASKIN® technology has the potential to revolutionize how these allergies are treated. With millions affected worldwide, the market for effective and non-invasive treatments is significant.

Investors should note the strategic importance of the upcoming conference. CEO Daniel Tassé’s participation in a fireside chat provides a platform for articulating the company’s vision and progress in clinical trials. This could lead to renewed interest among institutional and retail investors alike, particularly in light of ongoing trials for VIASKIN Peanut in young allergic patients.

As DBV Technologies advances its pipeline and garners more attention from key investment circles, stock performance might react positively to investor sentiment and clinical updates. The current focus on peanut allergies, a growing health concern, could position DBV favorably as its treatment options may offer a much-needed solution.

However, potential investors must also remain cautious. As a clinical-stage entity, DBV carries inherent risks related to the successful completion of trials, regulatory hurdles, and the volatility associated with biopharmaceutical stocks. Specific details regarding clinical trial timelines and results will be critical indicators of the company’s future performance and viability.

In summary, while DBV Technologies presents an exciting opportunity within the biopharmaceutical space, investors should maintain a balanced perspective, staying informed on clinical developments post-conference and assessing the overall market environment. Proactive engagement with updates will be vital for informed investment decisions going forward.